Treatment of acyclovir-unresponsive cutaneous herpes simplex virus infection with topically applied SP-303

Sharon Safrin, George McKinley, Mark McKeough, Dana Robinson, Spotswood L. Spruance

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The naturally occurring polyphenolic biopolymer SP-303 has in vitro activity against both HSV-1 and HSV-2, including strains that are resistant to acyclovir. Nine AIDS patients with acyclovir-unresponsive mucocutaneous herpes simplex virus infection were treated with thrice daily topical SP-303T ointment in an open-label pilot study. Although a transient decrease in lesion size was observed in 4 patients during study drug therapy, and 3 patients sustained a quantitative decrease in virus burden, neither complete healing nor cessation of virus shedding occurred in any patient. Seven patients complained of pain or burning upon application of the study ointment, causing 1 patient to terminate the study. In summary, application of SP-303T ointment effected no significant improvement in the clinical course of 9 AIDS patients with acyclovir-unresponsive HSV infection.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalAntiviral Research
Volume25
Issue number3-4
DOIs
StatePublished - Dec 1994
Externally publishedYes

Keywords

  • AIDS
  • Acyclovir-resistance
  • Herpes simplex
  • SP-303
  • Topica

Fingerprint

Dive into the research topics of 'Treatment of acyclovir-unresponsive cutaneous herpes simplex virus infection with topically applied SP-303'. Together they form a unique fingerprint.

Cite this